The population’s immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. A team of researchers has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses.
“People who have had strong immune responses to other human coronaviruses also have some protection against SARS-CoV-2 infection,” says the senior author.
In their study, the researchers used a specially developed assay to analyze antibody levels against four other human coronaviruses in 825 serum samples taken before SARS-CoV-2 emerged. They also examined 389 samples from donors infected with SARS-CoV-2. Combining these analyses with computer-based models enabled the team to precisely predict how well the antibodies would bind to and neutralize invading viruses.
The researchers were able to demonstrate that people who caught SARS-CoV-2 had lower levels of antibodies against coronaviruses that cause common colds compared to uninfected people. In addition, people with high levels of antibodies against harmless coronaviruses were less likely to have been hospitalized after catching SARS-CoV-2.
“Our study shows that a strong antibody response to human coronaviruses increases the level of antibodies against SARS-CoV-2. So someone who has gained immunity to harmless coronaviruses is therefore also better protected against severe SARS-CoV-2 infections,” says the author. This type of immune response is referred to as cross-reactivity, and it also occurs with T cell responses, the additional line of the immune system in the defense against infections.
People are only fully protected against SARS-CoV-2 shortly after they have recovered from an infection or have received an effective vaccination. This is when antibody levels against the virus are still very high. As these levels drop over time, infection is no longer prevented, but the immunological memory quickly reactivates the body’s defenses, the production of antibodies as well as the T cell defense.
“Of course, immune responses targeting SARS-CoV-2 that are mounted by the memory cells are far more effective than cross-reactive responses. But even though the protection isn’t absolute, cross-reactive immune responses shorten the infection and reduce its severity. And this is exactly what is also achieved through vaccination, just much, much more efficiently,” says the author.
It is not yet known whether this cross-reactivity also works in the opposite direction. Whether immunity to SARS-CoV-2 – achieved through vaccination, for example – also offers protection against other human coronaviruses still needs to be elucidated.
“If SARS-CoV-2 immunity also offers some degree of protection from infection with other coronaviruses, we would be a significant step closer to achieving comprehensive protection against other coronaviruses, including any new variants,” the virologist explains. This idea is also supported by the fact that cross-reactive protection is not only based on antibodies, but very likely also on T cells.
https://www.nature.com/articles/s41467-021-27040-x
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fmultifactorial&filter=22
Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity
- 1,519 views
- Added
Edited
Latest News
Neighboring synapses shape…
By newseditor
Posted 29 Mar
Complete vascularization of…
By newseditor
Posted 28 Mar
Immune cells identified as…
By newseditor
Posted 28 Mar
TB blood test which could d…
By newseditor
Posted 27 Mar
Propionate supplementation…
By newseditor
Posted 27 Mar
Other Top Stories
Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COV…
Read more
Ciliary body of the eye
Read more
How the brain paralyzes you while you sleep
Read more
Restricted diet and glucose uptake in the brain lead to longer life
Read more
A personalized neuromodulation approach to severe depression
Read more
Protocols
Spatial proteomics in neuro…
By newseditor
Posted 28 Mar
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Publications
Co-dependent excitatory and…
By newseditor
Posted 29 Mar
A microfluidic platform int…
By newseditor
Posted 28 Mar
Salmonella manipulates macr…
By newseditor
Posted 28 Mar
BHLHE40/41 regulate microgl…
By newseditor
Posted 28 Mar
Balancing neuronal activity…
By newseditor
Posted 28 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar